Disclosed is a formulation treating rheumatoid osteomyelitis, said formulation comprising an oral formulation and an external application formulation. The oral formulation has the following components by gram: 5-10 grams of poria, 5-10 grams of peeled ramulus cinnamomi, 5-10 grams of rhizoma atractylodis macrocephalae, 5-10 grams of roasted radix glycyrrhizae, 5-10 grams of caulis spatholobi, 5-10 grams of radix astragali, 5-10 grams of rhizoma atractylodis macrocephalae, 5-10 grams of radix glycyrrhizae, 5-10 grams of radix rehmanniae preparata, 15-20 grams of fructus corni, 5-10 grams of cortex moutan, 5-10 grams of rhizoma polygonati, 10-15 grams of walnut, 10-15 grams of rehmannia glutinosa, 15-20 grams of semen sesami nigrum, 15-20 grams of ox bone, and 10-15 grams of rhizoma cibotii. The external application formulation has the following components by gram: 10-20 grams of allium tuberosum root and leaf, 5-10 grams of eupolyphaga sinensis, 10-20 grams of herba menthae, 10-20 grams of caulis spatholobi, 10-20 grams of radix paeoniae rubra, 5-10 grams of earthworm, 10-15 grams of flos carthami, 10-15 grams of radix angelicae sinensis, 10-15 grams of radix aucklandiae, 10-20 grams of herba speranskiae tuberculatae, 10-20 grams of fructus chaenomelis, 10-20 grams of dipsacus asperoides, 10-20 grams of gendarussa ventricosa, 10-20 grams of herba gendarussae, and 10-20 grams of christia vespertilionis. The formulation is passed through a hundred mesh sieve and mixed with honey into a paste for use. The formulation treating rheumatoid osteomyelitis has few side effects, treats the cause of the disease, can be applied to the affected area, and reduces pain at the affected area.
Disclosed are an azithromycin pharmaceutical composition and a medical use thereof for cough relief. The azithromycin pharmaceutical composition contains azithromycin and a natural product compound (I) separated from dried rhizoma arisaematis and having a novel structure. When used individually, the azithromycin and the natural product compound (I) have an anti-inflammatory and cough-relieving effect. When used together, the two further improve the anti-inflammatory and cough-relieving effect, may be developed into an anti-inflammatory and cough-relieving drug, and have prominent substantive features and represent notable progress with respect to the prior art.
Disclosed are a bezafibrate pharmaceutical composition and an application thereof in rheumatoid arthritis. The bezafibrate pharmaceutical composition contains bezafibrate and a natural product compound (I) separated from dried clove buds and having a novel structure. The joint action of the bezafibrate and the compound (I) causes synovial cell stagnation in the G1 phase of the cell cycle, thereby inhibiting synovial cell proliferation, and treating rheumatoid arthritis. The treatment effect is better than the effect of the single action of the bezafibrate or the compound (I). The bezafibrate and compound (I) composition may be developed into a drug treating rheumatoid arthritis, and has prominent substantive features and represents notable progress with respect to the prior art.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
4.
AMRINONE PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF IN HYPERTENSION TREATMENT
Disclosed are an amrinone pharmaceutical composition and an application thereof in hypertension treatment. The amrinone pharmaceutical composition contains amrinone and a natural product compound (I) separated from dried blackberry lily rhizomes and having a novel structure. When used individually, the amrinone and the natural product compound (I) have a treatment effect on renovascular hypertension. When used together, the two further improve the treatment effect on renovascular hypertension, may be developed into a drug treating renovascular hypertension, and have prominent substantive features and represent notable progress with respect to the prior art.
C07D 307/00 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A drug treating bone dislocation later stage joint stiffness, the raw material composition being: 10-20 grams of fructus arenga pinnata, 5-10 grams of resina draconis, 5-10 grams of radix paeoniae rubra, 5-10 grams of cortex moutan, 15-30 grams of fructus citri sarcodactylis, 5-10 grams of ilex pernyi, 10-20 grams of herba lycopodii, 15-30 grams of herba speranskiae tuberculatae, 10-20 grams of caulis spatholobi, 10-20 grams of ramulus mori, 10-20 grams of radix gentianae macrophyllae, 5-15 grams of flos carthami, 5-15 grams of cortex acanthopanacis, 10-30 grams of semen brassicae, 15-30 grams of radix clematidis, and 15-30 grams of seaweed. The drug uses decoction or external hot compress means for administration, and has the effects of dispelling wind and eliminating dampness, relaxing tendons and muscles, and invigorating blood circulation and relieving pain.
Disclosed are a bifonazole pharmaceutical composition and a liver-protecting effect thereof. The bifonazole pharmaceutical composition contains bifonazole and a natural product compound (I) separated from dried fritillaria thunbergii bulbs and having a novel structure. The bifonazole and the compound (I) increase the GSH content in mouse liver tissue, decrease the MDA content, inhibit TG accumulation, and have a certain liver-protecting effect. When used together, the bifonazole and the compound (I) have a better treatment effect, may be developed into a liver-protecting drug, and have prominent substantive features and represent notable progress with respect to the prior art.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A Chinese medicine composition treating sprains and contusions, said composition comprising an oral Chinese medicine composition and an external application Chinese medicine composition. The oral Chinese medicine composition components are as follows, by gram: 5-10 grams of rhizoma chuanxiong, 5-20 grams of flos carthami, 5-20 grams of radix paeoniae rubra, 5-20 grams of myrrh, 5-20 grams of frankincense, 5-30 grams of herba centipedae, 5-15 grams of fructus gardeniae, 5-15 grams of squama manitis, 5-15 grams of rhubarb, 5-30 grams of cortex acanthopanacis, 10-40 grams of melastoma dodecandrum seeds, 5-30 grams of radix linderae, 5-15 grams of caulis hederae sinensis, and 5-10 grams of limnophila rugosa, dispensed and decocted by amount. The external application Chinese medicine composition components are as follows, by gram: 20 grams of caulis spatholobi, 10 grams of myrrh, 10 grams of notopterygium incisum, 10 grams of radix angelicae pubescentis, 30 grams of herba centipedae, 15 grams of radix dipsaci, and 10 grams of radix angelicae dahuricae, ground into a fine power, added to 5-10 grams of magnetic powder, and sieved and mixed uniformly.
Disclosed is a formulation treating joint ache, said formulation comprising oral formulation and external heat treatment components. The oral formulation components are as follows, by gram: 1-10 grams of poria, 1-10 grams of radix astragali, 1-10 grams of fructus schisandrae, 1-10 grams of radix codonopsis, 5-15 grams of sheep bone, 5-20 grams of ox marrow, 1-15 grams of bulbus allii macrostemi, 1-10 grams of fructus aurantii, 1-15 grams of semen persicae, 1-15 grams of panax notoginseng, 1-5 grams of folium ginkgo, 1-15 grams of radix aucklandiae, 5-15 grams of retinervus luffae fructus, 1-10 grams of flos carthami, 1-15 grams of herba abri, 1-15 grams of caulis spatholobi, and 1-15 grams of herba plantaginis. The external heat treatment components are as follows, by gram: 5-25 grams of rhizoma atractylodis, 5-15 grams of caulis spatholobi, 1-20 grams of semen strychni, 5-15 grams of herba plantaginis, 5-10 grams of ginger, 5-10 grams of pericarpium citri reticulatae, and 5-10 grams of radix bupleuri. The formulation treating joint ache uses oral and external local heat treatment means for internal and external administration, improving a treatment effect. The oral formulation components ease pain at the affected area. The formulation uses supplementation means to treat qi and blood stagnation and blood stasis and coagulation, improves immunity and metabolism, and reduces the possibility of relapse.
Disclosed is a formulation treating scalding, reducing inflammation and relieving pain, said formulation comprising an external application formulation and an oral formulation. The external application formulation comprises a paste formulation and a patch formulation. The paste formulation comprises the following, by gram: 5-20 grams of aloe, 5-20 grams of fresh torreya shell, 10-30 grams of raw radix sanguisorbae, 5-10 grams of raw rhubarb, 1-3 grams of borneol, 10-30 grams of cactus, 5-10 grams of sesame powder, 10-30 grams of fresh lotus leaf, 5-10 grams of camellia oil, 5-10 grams of olive oil, 1-3 grams of oyster oil, 1-3 grams of badger oil, and 5-20 grams of rice-washing water, mashed and mixed into a paste. The patch formulation comprises the following: white tofu slices, egg white, salt water, and sliced cucumber. The oral formulation comprises the following, by gram: 10-30 grams of fresh lotus leaf, 10-20 grams of fructus jujubae, and 5-15 grams of herba houttuyniae. The formulation treating scalding, reducing inflammation and relieving pain cools and refreshes the affected area during the treatment, performs inflammation reduction, swelling reduction, pain relief and itching relief on the affected area, promotes cellular regeneration, prevents bacteria and fungi from breeding, and achieves an effect of treating the root causes.
Disclosed is a formulation treating scalding, said formulation comprising the following components by gram: 10-30 grams of jujube tree bark, 10-50 grams of clarified pennisetum centrasiaticum water, 1-10 grams of tea leaf powder, 1-10 grams of herba menthae, 1-10 grams of dog oil, 10-30 grams of rhubarb, 10-30 grams of radix sanguisorbae, 10-50 grams of chrysanthemum, 5-30 grams of lotus leaf, 5-30 grams of honey, 10-30 grams of radix puerariae powder, 5-20 grams of tea tree oil, 5-10 grams of egg white, 5-15 grams of snail, 5-10 grams of aloe, and 1-10 grams of bulbus allii fistulosi. The formulation treating scalding uses external application means for administration, is applied easily, and has few side effects. A progressive course of treatment is used. The formulation cools and refreshes the affected area during the treatment, performs inflammation reduction, swelling reduction, pain relief and itching relief on the affected area, promotes cellular regeneration, prevents bacteria and fungi from breeding, does not leave scars, and achieves an effect of treating the root causes.
Disclosed are a benserazide hydrochloride pharmaceutical composition and a medical use thereof for lowering blood sugar. The benserazide hydrochloride pharmaceutical composition contains benserazide hydrochloride and a natural product compound (I) separated from dried rhizoma gastrodiae and having a novel structure. When used individually, the benserazide hydrochloride and the natural product compound (I) have an effect of lowering blood sugar. When used together, the two further improve the effect of lowering blood sugar, may be developed into a drug which lowers blood sugar, and have prominent substantive features and represent notable progress with respect to the prior art.
Disclosed is a formulation treating rheumatoid bone pain, said formulation comprising oral formulation and external heat treatment components. The oral formulation components are as follows, by gram: 1-10 grams of poria, 1-10 grams of radix astragali, 1-10 grams of fructus schisandrae, 1-10 grams of radix codonopsis, 5-15 grams of sheep bone, 5-20 grams of ox marrow, 1-15 grams of bulbus allii macrostemi, 1-10 grams of fructus aurantii, 1-15 grams of semen persicae, 1-15 grams of panax notoginseng, 1-5 grams of folium ginkgo, 1-15 grams of radix aucklandiae, 5-15 grams of retinervus luffae fructus, 1-10 grams of flos carthami, 1-15 grams of herba abri, 1-15 grams of caulis spatholobi, and 1-15 grams of herba plantaginis. The external heat treatment components are as follows, by gram: 5-25 grams of rhizoma atractylodis, 5-15 grams of caulis spatholobi, 1-20 grams of semen strychni, 5-15 grams of herba plantaginis, 5-10 grams of ginger, 5-10 grams of pericarpium citri reticulatae, and 5-10 grams of radix bupleuri. The formulation treating rheumatoid bone pain uses oral and external local heat treatment means for internal and external administration, improving a treatment effect. The oral formulation components ease pain at the affected area. The formulation uses supplementation means to treat qi and blood stagnation and blood stasis and coagulation, improves immunity and metabolism, and reduces the possibility of relapse.
A carbocisteine pharmaceutical composition and use thereof in preparing medications for treating leukemia. The carbocisteine pharmaceutical composition provided in the present invention comprises carbocisteine and a naturally produced compound (I) extracted from dry leaves of Pyrrosia lingua. The carbocisteine pharmaceutical composition has more significant leukemia treatment effects than that of carbocisteine and of the natural product used separately.
C07J 53/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by condensation with carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61P 35/02 - Antineoplastic agents specific for leukemia
14.
FORMULA FOR TREATING INJURIES FROM KNOCKS AND FALLS
Disclosed is a formula for treating injuries from knocks and falls. The components of the formula in gram are as follows: 1 to 15g of dragon's blood, 1 to 15g of Chinese angelica, 1 to 5g of safflower, 1 to 5g of ground beetle, 5 to 10g of red peony root, 5 to 15g of Adhatoda ventricosa, 5 to 15g of white justicia, 1 to 10g of frankincense, 1 to 10g of myrrh, 5 to 15g of pendulous monkshood root, 5 to 10g of orange fruit, 5 to 30g of peach seed, 5 to 10g of shiny-leaf prickly-ash, and 1 to 5g of borneol. The formula for treating injuries from knocks and falls in the present invention can treat injuries of tendons and bones, stagnant blood and distending pain, disharmony of qi and blood, and blocked meridian systems caused by injuries from knocks and falls, and can be administered both orally and topically. While treating stagnant blood, distending pain, and injuries of tendons and bones, the present formula also treats the disharmony of qi and blood as well as blocked meridian systems, being in accordance with the idea of treating both the fundamental and the incidental in traditional Chinese medicine.
A carbidopa pharmaceutical composition and medical use thereof for treating liver cancer are provided. The carbidopa pharmaceutical composition provided in the present invention comprises carbidopa and a naturally produced compound (I) having a new structure and isolated from dry roots and stems of Notopterygium incisum. When used independently, carbidopa and the natural product has treatment effects on liver cancer. When the two are used in conjunction, the liver cancer treatment effects are further improved, which can be developed into medications for treating liver cancer.
C07D 307/00 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
16.
CEFACLOR PHARMACEUTICAL COMPOSITION AND EFFECTS THEREOF FOR PROTECTING ACUTE LUNG INJURIES
Provided is a cefaclor pharmaceutical composition. The cefaclor pharmaceutical composition comprises cefaclor and a naturally produced compound (I) having a new structure and isolated from dry roots and stems of Acorus tatarinowii. When used independently, cefaclor and the natural product can prevent and treat lung injuries. When the two are used in conjunction, the lung injuries preventing and treating effects are further improved, which can be developed into medications for preventing and treating lung injuries.
C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61P 11/00 - Drugs for disorders of the respiratory system
17.
PHARMACEUTICAL COMPOSITION OF CHLORAMBUCIL AND MEDICAL USE THEREOF TO COUNTER DEPRESSION
Disclosed are a pharmaceutical composition of chlorambucil and medical uses thereof to counter depression. The present pharmaceutical composition of chlorambucil contains chlorambucil and a natural-product compound (1) extracted from the dried root of Pseudostellaria heterophylla and having a novel structure. Chlorambucil and the natural product working independently each have a certain efficacy in combating depression; when the two are used in conjunction, the anti-depressive effect is further improved, and anti-depressive medications can be developed therefrom. Compared to the prior art, the present invention is more substantive and shows significant improvements.
A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
C07D 303/32 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
Disclosed are a chlorprothixene pharmaceutical composition and effects thereof for protecting cerebral ischemia reperfusion injuries. The chlorprothixene pharmaceutical composition provided in the present invention comprises chlorprothixene and a naturally produced compound (I) having a new structure and isolated from Radix Adenophorae. When used independently, chlorprothixene and the natural product can reduce cerebral ischemia reperfusion injuries. When the two are used in conjunction, the cerebral ischemia reperfusion injuries preventing and treating effects are better, which can be developed into medications for preventing and treating cerebral ischemia reperfusion injuries. Compared to prior art, the present invention is more substantive and shows significant improvement.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
patents